Rumboldt Z, Janezic A, Knezević S, Marinković M, Simunić M, Lijić J
Klinika za unutarnje bolesti, KBC Firule, Split.
Lijec Vjesn. 1991 Mar-Apr;113(3-4):89-92.
The antihypertensive efficacy and safety of lisinopril (L), a novel ACE inhibitor, was compared to captopril (C), the known and already approved drug in our country in a multicenter double-blind Yugoslav trial. The study included 91 mild-to-moderate hypertensive patients of both sexes. Forty-six patients were randomized to receive captopril and 45 lisinopril. After a 2 week placebo, the examinees were administered either L in increasing dose of 10, 20, or 40 mg per day (amount necessary to achieve normotension), or C in a dosage of 25, 50, or 100 mg per day. During the 8 week formal trial L decreased the systolic blood pressure by an average of 14.9% from the initial values, and the diastolic pressure by some 15.2%. The same parameters were lowered on C by 11.2%, and 11.7%, respectively. Although the L effects were more pronounced, the observed differences did not reach the level of statistical significance (except for the dose-to-normotension relationship which was significantly better in the L group). It is concluded that both ACEIs under study showed comparable efficacy and tolerability, L being marginally more potent, and longer acting.
在一项多中心双盲的南斯拉夫试验中，将新型血管紧张素转换酶抑制剂赖诺普利（L）的降压疗效及安全性与我国已批准使用的已知药物卡托普利（C）进行了比较。该研究纳入了91例轻至中度高血压患者，男女均有。46例患者随机接受卡托普利治疗，45例接受赖诺普利治疗。在经过2周的安慰剂期后，受试者分别接受每天剂量递增的赖诺普利（10、20或40mg，达到血压正常所需的剂量）或每天剂量为25、50或100mg的卡托普利治疗。在为期8周的正式试验中，赖诺普利使收缩压较初始值平均降低了14.9%，舒张压降低了约15.2%。卡托普利使相同参数分别降低了11.2%和11.7%。尽管赖诺普利的效果更显著，但观察到的差异未达到统计学显著水平（除了达到血压正常的剂量关系在赖诺普利组明显更好）。结论是，所研究的两种血管紧张素转换酶抑制剂显示出相当的疗效和耐受性，赖诺普利的效力略强且作用时间更长。
